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ABSTRACT 
 
The hypothesis of atherosclerosis as an inflammatory process has been a Leitmotiv in cardiology for 
the past 20 years, and has now led to the launch of clinical trials aimed at testing whether drugs that 
primarily target inflammation can reduce cardiovascular events. Inflammation indeed drives all 
phases of atherosclerosis, from inception, through progression, and ultimately acute thrombotic 
complications (plaque rupture and probably plaque erosion). Since plaque rupture and erosion cause 
most acute coronary syndromes, appropriately tuned anti-inflammatory treatments should limit 
myocardial infarction and cardiovascular death. Beyond interrupting inflammation-related plaque 
disruption, such treatments might however also ameliorate the propensity to thrombosis once the 
trigger (plaque rupture or erosion) has occurred.  
Several lines of evidence support this view: experimental data document the role of inflammation in 
platelet activation, tissue factor-mediated coagulation, hyperfibrinogenemia, impaired activity of 
natural anticoagulants (including those expressed by endothelial cells), and reduced fibrinolytic 
activity. Supporting evidence also derives from the involvement of inflammation in venous 
thrombosis, a process that commonly occurs in the absence of traditional risk factors for 
atherosclerosis but associates with several inflammatory diseases including obesity. Ongoing trials, 
in addition to evaluating effects on primary outcomes, will afford the opportunity to probe the 
possibility that anti-inflammatory interventions that yield salutary changes in biomarkers of the 
thrombotic/fibrinolytic balance also translate into reduction of clinical events. 
 
Keywords: inflammation; thrombosis; methotrexate; colchicine; interleukin-1 receptor antagonist. 
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INTRODUCTION 
 
The hypothesis that inflammation drives atherosclerosis has gained currency in cardiovascular 
medicine. Inflammation contributes pivotally to all stages of atherosclerosis, from its inception 
(endothelial dysfunction, recruitment of immune cells, LDL modifications, foam cell formation, and 
apoptosis), and ultimately acute thrombotic complications triggered by plaque rupture or by plaque 
erosion (1). Inflammatory activation, involving multiple components of innate or acquired 
immunity (2), predisposes plaques to such acute complications (3). As corroborating 
histopathological evidence, circulating and easily measurable indices of inflammation, such as high- 
sensitivity (hs) C-reactive protein (CRP), myeloperoxidase, and leukocyte count, correlate with 
cardiovascular risk for events such as myocardial infarction, stroke and cardiovascular death (4, 5). 
Emerging biomarkers of inflammation in cardiovascular diseases include microparticles (MPs), 
which are small vesicles released from activated or apoptotic cells and containing signal 
transduction proteins, messenger (m)RNAs, and micro (mi)RNAs: inflammatory stimuli promote 
production of these particles that themselves can regulate inflammation (6). The links between 
inflammation and cardiovascular disease have inspired clinical trials in progress to test whether 
drugs that target inflammation primarily can reduce cardiovascular events (7-9).  
 
Thrombosis contributes critically to the natural history of atherosclerosis, often being the final actor 
by precipitating its acute clinical manifestations: rupture or erosion of atherosclerotic lesions expose 
the highly thrombogenic subendothelial layers to the flowing blood, and initiate platelet adhesion 
and aggregation and fibrin formation, precipitating clot formation (10). Inflammation can therefore 
cause thrombosis indirectly, by fostering atherosclerosis and its complications. Inflammation might, 
however, also promote clot accumulation directly, increasing the thrombotic risk as a consequence 
of increased blood thrombogenicity or impaired fibrinolysis, as first hypothesized over a decade ago 
(11). Support for this hypothesis derives from evidence of a role for inflammation in venous 
thromboembolism (VTE), a process that can occur in the absence of traditional risk factors for 
atherosclerosis in a vascular bed usually spared by this disease. Proof of this concept may now 
emerge from secondary analyses of ongoing clinical trials with anti-inflammatory agents.  
 
This review therefore aims to analyze the links between inflammation and thrombosis, to help set 
the stage for interpreting the results of clinical trials of anti-inflammatory agents in patients at risk 
for atherosclerotic events. Other reviews have recently covered the topic (12-16), but this paper 
focusses primarily on the clinical translation of these concepts. 
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ARTERIAL THROMBOSIS VERSUS VENOUS THROMBOEMBOLISM 
 
Traditional classifications have viewed arterial thrombosis and VTE as distinct pathological entities, 
with clear differentiating features. According to this classical schema, white thrombus characterizes 
the nascent arterial thrombosis, composed of an aggregate of platelets enmeshed in fibrin strands at 
the site of plaque rupture or erosion; while clot propagation (red thrombus) consists mostly of red 
blood cells entrapped in a growing fibrin network. Such propagation of the initial thrombus often 
occurs in cases of total arterial occlusion, such as in ST segment-elevation myocardial infarction 
(STEMI). Conversely, according to the classical view, venous thrombosis typically starts with the 
formation of a red thrombus, less dependent on platelets. Of the trio of precipitating factors 
postulated by Virchow, in VTE vessel wall injury traditionally lags in pathogenic relevance after 
hypercoagulability and stasis. Inherited thrombophilia, due to factor (F) V variants leading to 
resistance to activated protein C (APC) or the prothrombin variant G20210A, or the rarer natural 
anticoagulant antithrombin (AT) or protein C or protein S deficiencies, but also acquired 
thrombophilia in the setting of lupus anticoagulant or the anti-phospholipid antibody syndrome, 
increase the risk of VTE. Their link with arterial thrombosis (except in the case of the lupus 
anticoagulant) remains, however, unclear (17-19). 
This classical – totally dichotomous – view has recently come under scrutiny.  Current concepts link 
the pathogenesis of arterial and venous thrombosis more tightly. Clinical evidence supports this 
reassessment: patients with arterial thrombosis have an increased risk of venous thrombotic events; 
a history of VTE associates with the risk of future arterial events; and the two conditions share 
several risk factors, including age, obesity, hypercholesterolemia, hypertension, lupus 
anticoagulant, hyperhomocysteinemia, microalbuminuria and non-alcoholic hepatosteatosis. 
Moreover, evidence has emerged that platelets do indeed participate in venous thrombosis to a 
degree previously underestimated (20, 21). This commonality has therapeutic implications: current 
studies support roles for aspirin, low-molecular weight heparin and warfarin in the treatment of both 
venous and arterial thrombosis (22-27). As a consequence, the silo thinking of VTE and arterial 
thrombosis as completely separate entities has given place to a new concept that includes VTE in a 
panvascular syndrome that comprises thrombotic complications affecting the veins as well as the 
coronary, peripheral, and cerebrovascular arterial beds (28). The prevalence of carotid plaques in 
patients with unexplained venous thrombosis that exceeds that in those with events attributable to a 
well-identified cause (47.1% vs 27.4%), has stimulated consideration of a systemic thrombophilic 
state as an underlying feature (22). More recent evidence supports inflammation as a common 
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pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of 
inflammation-induced thrombosis (26). 
 
 
RECIPROCAL RELATIONS BETWEEN INFLAMMATION AND THROMBOSIS 
 
Inflammation and hemostasis can participate in a pathogenic positive feedback loop: inflammation 
unleashes hemostatic mechanisms, which in turn can amplify inflammation (29-31). Both 
mechanisms participate in host defenses that help eliminate or contain pathogens, limit tissue 
damage, and – in order to resolve – evoke counter-regulatory mechanisms that tend to restore 
homeostasis. In particular, fibrin deposition can serve to wall-off invading agents and confine the 
consequent inflammatory response to a limited area, e.g., abscess formation in coagulase-positive S. 
aureus infections (32). An exaggerated or insufficiently controlled thrombotic response may 
however contribute to disease, such as in the case of the systemic activation occurring with severe 
infection or sepsis. This scenario results from a spatially uncontrolled systemic inflammatory 
response, and leads to multiple organ dysfunction and possibly failure in the setting of disseminated 
intravascular coagulation (32, 33). 
 
The interrelationship between inflammation and hemostasis reaches back to the early stages of 
evolution: invertebrates have a single cell type, the hemocyte, which can perform both anti-
inflammatory/immune and hemostatic functions. This overlap between innate immunity and 
hemostasis has endured over millions of years of evolution (34). Cross talk between these the two 
functions involves cell receptor-mediated signaling, cell-cell interactions, and the production of 
cell-derived microvesicles, with dual functions, by endothelial cells, leukocytes and platelets (35).  
 
Inflammation affects the hemostatic system leading to a procoagulant state by affecting all cellular 
and humoral components of hemostasis, including vascular endothelial cells, platelets, the plasma 
coagulation cascade, the physiologic anticoagulant pathways, and fibrinolytic activity (31). 
Likewise, many elements of the hemostatic system, such as platelets, thrombin, FXa, the tissue 
factor (TF)-FVIIa complex, fibrinogen, and fibrin, can augment inflammation. Thrombin activation 
not only promotes fibrin generation, but also – by cleaving protease-activated receptors (PARs) – 
promotes the production of pro-inflammatory mediators, such as cytokines, chemokines, growth 
factors, and leukocyte adhesion molecules. Indeed, the crosstalk between inflammation and 
thrombosis generates a vicious circle that can amplify pathological processes and tissue damage. 
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Thus, therapeutic targeting of either coagulation or inflammation may influence the onset and the 
progression of multiple diseases the pathogenesis of which involves both processes (31, 32, 36). 
 
 
THROMBOSIS AS AN INFLAMMATORY PROCESS 
 
Inflammation can perturb the hemostatic system, promoting a pro-thrombotic state, through several 
mechanisms (summarized in Table 1 and Figure 1): in particular, inflammation affects endothelial 
function, increases platelet reactivity, and activates plasma coagulation by activating procoagulant 
mechanisms and muting anticoagulant mediators (37).  
 
Endothelial cell dysfunction 
 
Vascular endothelial cells furnish an antithrombotic surface that, in normal conditions, prevents the 
inappropriate activation of hemostasis through a balanced production of pro- and anti-inflammatory, 
pro- and anti-coagulant, anti- and pro-fibrinolytic molecules. Inflammation leads to an imbalance 
favoring procoagulant and antifibrinolytic components, including von Willebrand factor (VWF), 
thromboxane (TX)A2, plasminogen activator inhibitor (PAI)-1, TF, and cell adhesion molecules, 
causing a shift from an anticoagulant, anti-inflammatory and vasodilatory endothelial suite of 
functions to a proinflammatory and prothrombotic state. Endothelial cells contribute to 
inflammation-induced thrombosis acting at all levels of hemostasis, including the activation of 
platelets and other inflammatory cells, TF-mediated thrombin generation, reduction of physiologic 
anticoagulant functions, and the reduction/suppression of fibrinolytic activity. A number of small 
molecules also serve as pro- or anti-inflammatory mediators that may have impacts on thrombosis 
and hemostasis, including prostaglandins, reactive oxygen species, nitric oxide, and regulators of 
tissue remodeling enzymes (31) (Figure 1).  
 
Platelet activation 
 
Platelets not only participate in primary hemostasis, but also contribute to inflammation-induced 
thrombosis. Platelet activators include not only thrombin and ADP, but also molecules implicated in 
mediating inflammation, such as bacterial endotoxins (38) and the lipid mediator platelet-activating 
factor (PAF) (38). Activated platelets express on their surface or secrete pro-inflammatory and pro-
coagulant substances, such as adhesion molecules, growth factors, cytokines (including 
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CD154/CD40 ligand) and the inhibitor of fibrinolysis PAI-1, and they allow the surface assembly of 
coagulation factors (39). Moreover, platelets contribute to a systemic prothrombotic state through 
the generation of TF-expressing MPs and the expression of P-selectin, which, through the activation 
of the transcription factor nuclear factor (NF)-κB, in turn promotes the production of 
proinflammatory molecules by endothelial cells and leukocytes, as well as the expression of TF in 
monocytes, endothelial and also smooth muscle cells (31, 32, 36, 40). 
 
Modulation of plasma coagulation 
 
TF acts as the pivotal initiator of inflammation-induced thrombin generation, thus bridging 
inflammation and thrombosis (32). Various cell types constitutively express this transmembrane 
molecule. Most TF-expressing cells localize in tissues that do not contact blood directly, such as in 
the adventitial layer of blood vessels. TF comes in contact with blood in case of breaches in 
vascular integrity or when induced in vascular endothelial cells or circulating blood cells (31, 32, 
36). The source of TF may differ in various inflammatory conditions: in atherosclerotic plaques, 
macrophage-derived foam cells account for much TF expression, likely as a result of stimulation by 
pro-inflammatory cytokines such as CD154/CD40 ligand (41). Rupture of atheromatous plaques 
permits contact of blood coagulation factors with TF residing within the lesion (32, 42). In sepsis, 
TF expressed on the endothelium and on circulating mononuclear cells in response to endotoxins 
and/or proinflammatory cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-1, or IL-6 
(43), leads to systemic activation of coagulation (31, 32). Cells that do not ordinarily express TF 
can acquire it from MPs (34, 36). MPs act as biological shuttles, enabling otherwise unusual cell 
interactions, and may represent one important intersection between thrombosis and inflammation by 
furnishing a reservoir of TF released from cells with either inducible (monocytes, macrophages, 
endothelial cells and platelets) or constitutive expression (cells in the adventitia or in certain 
tumors). Stimuli for TF production and its release in MPs include endotoxin, cytokines, 
microorganisms, thrombin, low shear stress, oxidative stress, hyperglycemia, smoking, 
dyslipidemia, complement and immune reaction. Beside the circulating pool of MPs, a pool of MPs 
sequestered in the plaque provides another TF reservoir in atherothrombosis. Apoptotic 
macrophages and smooth muscle cells may contribute to accumulation of TF-bearing MPs in the 
lipid core (6). TF exposed to blood binds to FVIIa, which then catalyzes the conversion of FX into 
FXa directly or through the activation of FIX. FXa, FVa, prothrombin (FII) and calcium constitute 
key components of the prothrombinase complex on the surface of activated cells, able to generate 
thrombin, which then converts fibrinogen into fibrin (31, 32, 39, 44).  
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The main physiological anticoagulant mechanisms include antithrombin (AT), the protein C system 
and TF pathway inhibitor (TFPI). These mediators function to prevent blood clotting in 
physiological conditions and to limit coagulation activation to the site of vascular injury. 
Impairment in their function represents an important mechanism of the procoagulant state 
associated with inflammation (31). Antithrombin (AT, formerly AT III), a serine protease inhibitor, 
targets thrombin and FXa. AT levels decrease markedly in inflammation because of consumption 
(related to ongoing thrombin generation), impaired synthesis (as a result of the acute phase 
response), and degradation by neutrophil elastase (32). Additionally, cytokines can reduce the 
synthesis of glycosaminoglycans on the endothelial surface, which otherwise normally promote the 
anticoagulant activity of AT (31).  
Protein C undergoes activation by thrombin bound to the endothelial cell membrane molecule 
thrombomodulin. Activated protein C (APC) cleaves the essential cofactors of coagulation FVa and 
FVIIIa. In addition, by binding to the endothelial protein C receptor (EPCR), it increases its own 
activation mediated by the thrombomodulin–thrombin complex, and inhibits induced TF expression 
on mononuclear cells. Inflammation limits the protein C system due to reduction of 
thrombomodulin, produced by TNF and IL-1 on the endothelial surface (36).  
The third physiological anticoagulant mechanism is TFPI, a serine protease inhibitor of the TF-
FVIIa complex that attaches to the endothelium via glycosaminoglycans. The impact of 
inflammation on TFPI function has received little attention. Proinflammatory cytokines can reduce 
glycosaminoglycan synthesis in endothelial cells, affecting TFPI function (31, 32).  
 
The fibrinolytic system also modulates thrombosis induced by inflammation. Plasmin lyses clots by 
degrading fibrin. Generation of plasmin from plasminogen depends on the action of tissue-type 
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Type-1 
plasminogen activator inhibitor (PAI-1) can inhibit both of these plasminogen activators, reducing 
their fibrinolytic potential. Inflammatory states transiently increase fibrinolytic activity, due to the 
release of tPA stored in vascular endothelial cells, followed by a more sustained increase of 
endothelial PAI-1 production induced by TNF and IL-1. Moreover, platelets also contain preformed 
PAI-1 stored in alpha-granules, and release it upon their activation. Thus, inflammatory signaling 
yields a net inhibition of fibrinolysis, contributing to inflammation-induced thrombus accumulation 
(31, 32).  
 
Fibrinogen also participates in the inflammatory response. The liver synthesizes fibrinogen, an 
acute phase reactant the blood concentration of which increases in conditions characterized by 
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infection or inflammation (44). Hyperfibrinogenemia not only serves as a biomarker of thrombotic 
risk, but can contribute causally to both venous and arterial thrombosis (45). An elevated plasma 
fibrinogen level (>4 mg/mL) associates significantly with increased risk of VTE in a concentration-
dependent manner (45). Elevated fibrinogen levels increase blood viscosity and red blood cell 
agglutination in the setting of a hyperviscosity syndrome that increases blood flow shear stress, 
leading itself to endothelial cell and platelet activation (44). Moreover, several clinical studies have 
suggested that abnormal fibrin accumulation modulates thrombosis: clots with increased fibrin fiber 
density and resistance to fibrinolysis associate with both arterial and venous thrombosis (46-52). 
The structure of the fibrin network reflects fibrinogen and thrombin concentration: indeed, elevated 
levels of fibrinogen and thrombin increase fibrin network density, clot stiffness, and the resistance 
of thrombi to fibrinolysis, contributing to clot accumulation and persistence (45).  
Neutrophil extracellular traps: a novel link between innate immunity and thrombosis 
Polymorphonuclear leukocytes participate pivotally in host defenses against infection or injury.  
These neutrophilic leukocytes, attracted to sites of microbial invasion or tissue damage, release their 
granular contents, produce reactive oxygen species, generate lipid mediators, and then die, a process 
probably involving apoptosis. In the throes of death, neutrophils release strands of their nuclear 
DNA that become decorated with various proteins, among them the pro-oxidant enzyme 
myeloperoxidase, and the pro-coagulant tissue factor. These strands of extruded DNA provide a 
“solid state” reactor at sites of acute inflammation that can locally amplify oxidant stress and trigger 
thrombosis. Moreover, in combination with a fibrin network, these structures, known as neutrophil 
extracellular traps or NETs, participate in the propagation thrombosis, entrap platelets, and thus 
promote local thrombosis. 
When NETs form on the intimal surface of veins or arteries, they can amplify and extend local 
thrombosis. Recent experimental work has documented that NETs provide a scaffold for thrombus 
formation, and participate in platelet activation (20). Further observations implicated NETs in 
experimental (53) and in human venous thrombosis (54). Markers of NET formation correlate with 
the severity of human coronary atherosclerosis and evidence for a prothrombotic state (13). In 
addition, NETs themselves can amplify inflammation by activating the NLRP3 inflammasome, a 
multimeric intracellular assembly of proteins that generates the active forms of the pro-
inflammatory cytokines IL-1 beta and IL-18 (55). Thus, NETs mediate a newly recognized 
mechanism that links innate immunity and inflammation. This pathway likely promotes the 
prolongation and propagation of local inflammatory and thrombotic responses in both veins and 
arteries (56). 
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CLINICAL IMPLICATIONS  
 
The increased thrombotic risk encountered in patients with conditions characterized by a 
proinflammatory state, such as autoimmune diseases, infections and sepsis, underscores the links 
between inflammation and thrombosis (Table 2 and Figure 2) (57). Patients with rheumatoid 
arthritis have a 1.5 to 6 times increased risk of VTE, a reflection in part of their active systemic 
inflammation. Inflammatory cytokines implicated in rheumatologic diseases, such as IL-6, IL-8, or 
TNF-α, can activate hemostatic pathways promoting a thrombotic tendency, and also inhibit 
fibrinolysis (58-61). Thromboembolic complications, both venous and arterial, also commonly 
cause serious extra-intestinal complications in patients with inflammatory bowel diseases 
inflammation likely contributes to their elevated risk of thrombosis (62-64).  
 
The acute phase of two prototypic autoimmune skin diseases, chronic autoimmune urticaria and 
bullous pemphigoid, also associate with hypercoagulability, although only the latter condition has 
clearly increased thrombotic risk. The crosstalk between inflammation and thrombosis likely 
participates in the pathophysiology of both autoimmune diseases. The stronger activation of 
systemic coagulation in patients with bullous pemphigoid may contribute to the increased 
thrombotic risk. In these patients, the reduction in coagulation activation observed after 
immunosuppressive treatments may contribute to the healing of cutaneous manifestations, but also 
to the reduction of the associated thrombotic risk (65). 
 
Systemic inflammation can participate in the pathogenesis of the increased rates of thrombosis 
documented in other autoimmune diseases, such as autoimmune hemolytic anemia, immune 
thrombocytopenic purpura, systemic lupus erythematosus, systemic vasculitides, the 
antiphospholipid antibody syndrome, Sjögren’s syndrome, and systemic sclerosis (66-70). 
Similarly, increased microvascular thrombosis is found in chronic and acute infections and in 
sepsis, where it contributes to multiple organ dysfunction. Indeed, strategies to manage 
microvascular thrombosis appear to reduce morbidity and mortality outcome in clinical studies (71, 
72), illustrating the antithrombotic potential of aggressive anti-inflammatory treatment during the 
active phases of several types of diseases. 
 
 
ANTI-INFLAMMATORY THERAPIES IN CARDIOVASCULAR DISEASE 
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The inflammatory aspects of atherosclerosis and its complications have already inspired several 
clinical trials aimed at testing the possibility that anti-inflammatory therapies will reduce 
cardiovascular events in various settings of risk, including trials with COX-2 inhibitors (coxibs), 
anti-TNF agents, etc. (5, 8, 73). Most such trials have either used agents not selective for targeting 
inflammation, or have lacked sufficient power to address cardiovascular endpoints.  
Statin treatment reduces the incidence of all-cause mortality and major coronary events in 
appropriately selected individuals in the setting of both secondary and primary prevention (74). 
Statin therapy, beyond its effect on lipids, reduces the concentration of CRP (75), a biomarker that 
adds to prediction of risk of a first myocardial infarction and ischemic stroke in healthy men and 
women (76, 77). Patients who achieve lower CRP levels on statin therapy have better clinical 
outcomes regardless of low-density lipoprotein (LDL) cholesterol levels (78). The Justification for 
the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) tested 
the proposition that inflammatory status could identify a group of individuals in primary prevention 
that would benefit from statin treatment. This study demonstrated that rosuvastatin (20 mg daily) 
reduced cardiovascular risk in individuals with above median levels of CRP (>2 mg/L) and below 
median LDL-cholesterol values (LDL <130 mg/dL) (79). Yet, because statins lower both 
cholesterol LDL and CRP, JUPITER did not aim to test whether rosuvastatin reduced events by an 
anti-inflammatory mechanism independent of reduced LDL. Highly relevant to the thesis of this 
review, JUPITER also documented a reduction of both provoked and unprovoked VTE, likely 
related to the anti-inflammatory effect of the statin or a conceivably direct antithrombotic effect, as 
VTE risk depends little if at all on LDL (80).  
 
More recently, however, trials with drugs that target inflammation more specifically have attempted 
to avoid confounding due to effects on other determinants of cardiovascular risk. The Low-Dose 
Colchicine (LoDoCo) trial used a prospective randomized open blinded endpoint (PROBE) design 
to test the effects of colchicine on cardiovascular events in a relatively small but intriguing study. 
The results provided strong preliminary evidence in support of the concept that an anti-
inflammatory drug could reduce cardiovascular events (7). This study points to the urgent need for a 
larger double-blind placebo-controlled trial of colchicine in the context of cardiovascular 
prevention. The LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify 
outcomes after an acute coronary syndromE (LATITUDE)-TIMI-60 study investigated the effects 
an inhibitor of p38 MAP kinase, losmapimod, on current events in patients with acute coronary 
Page 11 of 40 Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
De Caterina R. et al., TH-16-03-0246 – R1, page 12 
 
syndromes. The part A of the study followed over 3,500 patients, and the results did not support 
expanding of this preliminary part into a larger-scale outcome trial (81). 
Two phase III studies (Table 3) currently underway provide further opportunities to test anti-
inflammatory interventions of distinct mechanisms on recurrent cardiovascular events in at-risk 
populations. The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) has 
enrolled patients stable post-myocardial infarction with hsCRP >2 mg/L despite secondary 
prevention strategies. CANTOS examines whether canakinumab, a human monoclonal antibody 
that selectively neutralizes IL-1β, will reduce rates of recurrent myocardial infarction, stroke, and 
cardiovascular death (82). A specific modulation of the IL-1 pathway as a therapeutic strategy in the 
atherosclerosis finds support in the recent appreciation of the role of the “inflammasome” in 
atherogenesis, as outlined above (55), since caspase-1, an end-product of the inflammasome, 
cleaves the pro-inflammatory cytokines IL-1β and  IL-18 into their active forms, which when 
released from cells, promote local inflammation (83-85). The discovery that cholesterol crystals 
activate the inflammasome in human macrophages, resulting in the release of active IL-1β 
underscores the interrelation beween atherogenic risk factors and vascular inflammation (86, 87).  
The Cardiovascular Inflammation Reduction Trial (CIRT) is enrolling patients with elements of the 
metabolic syndrome and post-MI or with stable multivessel coronary artery disease. Distinct from 
CANTOS, that studies a strategy interfering with one specific anti-inflammatory mediator, CIRT 
will evaluate the efficacy in reducing cardiovascular events of very low-dose (10-25 mg weekly) 
methotrexate, a broadly acting anti-inflammatory drug commonly used for the treatment of 
rheumatoid arthritis (88, 89). Since plaque rupture and erosion trigger most arterial thromboses, 
these treatments may limit reduce the hard endpoints by reducing inflammatory drivers of 
thrombosis and impaired fibrinolysis. The hypothesis of inflammation-induced thrombosis predicts 
a reduction of VTE events, as prespecified in the trial designs. Indeed these ongoing trials could 
provide a clinical confirmation of the direct role played by inflammation in the pathogenesis of 
thrombosis.  
A third ongoing phase IV trial of the effects of anti-inflammatory therapy on the incidence of 
cardiovascular events is ENTRACTE (A Clinical Outcomes Study to Evaluate the Effects of IL-6 
Receptor Blockade With Tocilizumab in Comparison With Etanercept on the Rate of 
Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis), which compares 
tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, to etanercept, a soluble 
TNF receptor, in patients with rheumatoid arthritis (Table 3) (90) 
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CONCLUSIONS  
Anti-inflammatory therapy to prevent atherothrombotic events, as in other therapeutic areas, may 
entail unwanted effects. The inflammatory and immune responses contribute importantly to host 
defenses. These pathways participate in combatting infections, in tumor surveillance, as well as in 
wound healing and tissue repair. Hence, the quest to identify anti-inflammatory therapies that will 
selectively inhibit effector arms of innate and adaptive immunity involved in atherothombosis 
without causing undue interruption of host defense mechanisms may require multiple attempts.  
While rodent and other experiments can prove highly informative from the mechanistic viewpoint, 
they seldom predict accurately the full spectrum of efficacy or of adverse effects encountered in 
clinical trials (91). Moreover, the high degree of redundancy in inflammatory signaling pathways 
presents a challenge, but also a potential advantage. A myriad of mediators (e.g., cytokines, 
chemokines, and lipid mediators) may promote the pathogenesis of the thrombotic complications of 
atherosclerosis. This menu provides a plethora of potential targets for intervention. From one 
perspective, this redundancy raises the hope that narrow blockade of a single mediator may provide 
Paul Ehrlich's hypothesized "magic bullet" to interrupt a pathogenic pathway, while the 
complementary mechanisms will limit undesired actions. Yet, the very multiplicity of mediators in 
host defenses indicates that the mere interruption of one of dozens of possible targets may not 
suffice to reduce events, as parallel pathways provide detours and bypasses should only one path be 
blocked. The survival value of host defenses has doubtless fostered this ability to compensate. 
In practical terms, testing of a particular therapy in large-scale clinical trials requires not only a 
strong rationale, but also a degree of assurance regarding adverse actions. A number of biological 
approaches to neutralizing cytokine activities are making into the clinic, but for all considerations 
on the benefit-risk profile will be pivotal. For example, neutralizing IL-6 with a monoclonal 
antibody merits consideration as a therapeutic option for cardiovascular disease. Strong genetic 
evidence suggests causality of IL-6 in atherothrombotic events (92, 93). Yet, adverse perturbations 
and lipid profile might limit the utility of anti-IL-6 strategies in patients with established risk for 
atherosclerosis. Anti-TNF agents have transformed rheumatology, dermatology, and 
gastroenterology. Studies of TNF neutralization in patients with heart failure, however, not only 
failed to confer benefit, but raised notes of caution regarding adverse effects (94). On the other 
hand, lipid risk factors beyond LDL offer other potential targets for anti-inflammatory intervention. 
LDL itself associates weakly with indices of information such as hsCRP. Yet, triglyceride-rich 
lipoproteins correlate strongly with this biomarker of inflammation (95). Thus, interventions that 
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target triglyceride-rich lipoproteins or their associated pathogenic apolipoproteins might provide 
another avenue to quelling inflammation in atherothrombosis (96). 
From the perspective of antithrombotic therapy, anti-inflammatory therapy does provide an avenue 
to reducing thrombotic risk without increasing bleeding. This happened in JUPITER, where 
rosuvastatin decreased the risk of deep venous thrombosis without producing an anticoagulant 
effect (97). Study of the anti-inflammatory treatments currently under scrutiny will not only 
evaluate efficacy, but also determine the safety of the interventions in individuals with heightened 
cardiovascular risk. 
In sum, inflammation and thrombosis intertwine inextricably (30). Anti-inflammatory therapies may 
prevent thrombotic events not only by affecting the "solid-state" of the atherosclerotic plaque, but 
also by favorable effects on the "fluid phase" of the blood (11). The concerted effect of anti-
inflammatory therapy on both compartments provides a potential new avenue for preventing 
thrombotic complications without augmenting bleeding risk, which is the Holy Grail of our field. 
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LEGEND TO FIGURES 
 
Figure 1. Inflammation (top right) induces a pro-thrombotic state (bottom left) that influences 
plasma coagulation, endothelial cells, and platelets. Inflammation stimulates TF production 
triggering the coagulation cascade, inhibits the three main physiological anticoagulant mechanisms 
(AT III, APC and TFPI) and increases endothelial PAI-1 production inhibiting fibrinolysis. 
Inflammation favors the endothelial production of pro-coagulant and anti-fibrinolytic components, 
including VWF, TXA2, PAI-1, TF and cell adhesion molecules, causing a shift from an 
anticoagulant, anti-inflammatory and vasodilatory endothelial functions to a pro-inflammatory and 
pro-thrombotic state. Moreover, inflammation activates platelets, which express on their surface or 
secrete pro-inflammatory and pro-coagulant substances, such as adhesion molecules, growth 
factors, cytokines PAI-1, TF-expressing MPs and P-selectin.  
Abbreviations: Ab: antibodies; APC: activated protein C; AT III: antithrombin III; MPs: 
microparticles; PAI-1: plasminogen activator inhibitor-1; TF: tissue factor; TFPI: tissue factor 
pathway inhibitor; t-PA: tissue-type plasminogen activator; TXA2: thromboxane A2; u-PA: 
urokinase-type plasminogen activator; VWF: von Willebrand factor; WBC: white blood cells.  
Figure 2. Increased thrombotic risk in diseases with a proinflammatory state. 
Page 24 of 40Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
De Caterina R. et al., TH-16-03-0246 – R1, page 25 
 
 
Table 1: Direct mechanisms of inflammation-induced thrombosis (37)  
  
Endothelial cell dysfunction and activation 
Platelet activation 
Modulation of plasma coagulation  
Augmented pro-coagulant functions Tissue Factor-mediated activation of coagulation 
Reduction of endogenous anticoagulants: Antithrombin, Tissue Factor pathway   
inhibitor (TFPI); Protein C pathway 
Inhibition of fibrinolytic activity 
Hyperfibrinogenemia 
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Table 2: Increased thrombotic risk in diseases with a pro-inflammatory state (57) 
Autoimmune diseases 
Rheumatoid arthritis, inflammatory bowel diseases, chronic autoimmune urticaria, 
bullous pemphigoid,  autoimmune hemolytic anemia, immune thrombocytopenic 
purpura, systemic lupus erythematosus, systemic vasculitides, the antiphospholipid 
antibody syndrome, Sjögren’s syndrome and systemic sclerosis  
Infections and sepsis Chronic and acute 
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Table 3. Ongoing phase III studies on drugs specifically targeting inflammation 
TRIAL DESIGN AIM DRUG TESTED PRIMARY ENDPOINT SECONDARY ENDPOINTS REFERENCES
CANTOS (Canakinumab Anti-
inflammatory Thrombosis Outcomes 
Study)
A phase III, 
randomized, double-
blind, placebo-
controlled, multi-
center, event-driven 
trial 
Tests if reducing inflammation can 
reduce rates of recurrent 
cardiovascular events among stable 
post-myocardial infarction patients 
who remain at elevated vascular 
risk  (hsCRP ≥2mg/L) despite usual 
care, including statin therapy
Low-dose 
methotrexate
Composite of non-fatal 
myocardial infarction, non-
fatal stroke, or 
cardiovascular death
Total mortality, hospitalization for 
unstable angina requiring 
revascularization, new onset 
diabetes
82
CIRT (Cardiovascular Inflammation 
Reduction Trial)
A phase III, 
randomized, double-
blind, placebo-
controlled, multi-
center, event-driven 
trial 
Tests if reducing inflammation 
among stable coronary artery 
disease patients (prior myocardial 
infarction or angiographically 
demonstrated multivessel coronary 
artery disease) with type 2 diabetes 
or metabolic syndrome can reduce 
rates of cardiovascular events 
Canakinumab, a 
human monoclonal 
antibody 
that neutralizes 
interleukin-1β
Composite of 
cardiovascular death, non-
fatal myocardial infarction 
and stroke
All-cause mortality, percutaneous 
or surgical coronary 
revascularization, hospitalization for 
congestive heart failure, incident 
venous thromboebolism,  incident 
atrial fibrillation, incident diabetes, 
Incident peripheral artery disease, 
clinically worsening aortic stenosis 
88, 89
ENTRACTE (A Clinical Outcomes 
Study to Evaluate the Effects of IL-6 
Receptor Blockade With Tocilizumab in 
Comparison With Etanercept on the 
Rate of Cardiovascular Events in 
Patients With Moderate to Severe 
Rheumatoid Arthritis)
A phase IV, 
randomized, open-
label, parallel-group, 
multicenter study
Evaluates the frequency of 
cardiovascular events on tocilizumab 
in comparison with etanercept in 
participants with rheumatoid 
arthritis.
Tocilizumab,  a 
humanized 
monoclonal antibody 
against the interleukin-
6 receptor and 
etanercept a soluble 
TNF receptor
Composite of 
cardiovascular death, non-
fatal myocardial infarction 
and non-fatal stroke
A composite endpoint of major 
cardiovascular events plus non-
fatal coronary revascularization 
procedures and hospitalization for 
unstable angina; as well as 
investigating the frequency of 
adverse events and serious 
adverse events
90
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Table 1: Direct mechanisms of inflammation-induced thrombosis 
Endothelial cell dysfunction and activation
Platelet activation
Modulation of plasma coagulation 
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Table 1: Direct mechanisms of inflammation-induced thrombosis (37)
Endothelial cell dysfunction and activation
Platelet activation
Modulation of plasma coagulation 
Augmented pro-coagulant functions Tissue Factor-mediated activation of coagulation
Reduction of endogenous anticoagulants: Antithrombin, Tissue Factor pathway  
inhibitor (TFPI); Protein C pathway
Inhibition of fibrinolytic activity
Hyperfibrinogenemia
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Table 2: Increased thrombotic risk in diseases with a pro-inflammatory state 
Autoimmune diseases
Infections and sepsis
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Table 2: Increased thrombotic risk in diseases with a pro-inflammatory state (57)
Rheumatoid arthritis, inflammatory bowel diseases, chronic autoimmune urticaria, bullous 
pemphigoid,  autoimmune hemolytic anemia, immune thrombocytopenic purpura, systemic 
lupus erythematosus, systemic vasculitides, the antiphospholipid antibody syndrome, 
Sjögren’s syndrome and systemic sclerosis 
Chronic and acute
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Table 3. Ongoing phase III studies on drugs specifically targeting inflammation 
TRIAL DESIGN
CANTOS (Canakinumab Anti-
inflammatory Thrombosis Outcomes 
Study)
A phase III, 
randomized, double-
blind, placebo-
controlled, multi-
center, event-driven 
trial 
CIRT (Cardiovascular Inflammation 
Reduction Trial)
A phase III, 
randomized, double-
blind, placebo-
controlled, multi-
center, event-driven 
trial 
ENTRACTE (A Clinical Outcomes 
Study to Evaluate the Effects of IL-6 
Receptor Blockade With Tocilizumab in 
Comparison With Etanercept on the 
Rate of Cardiovascular Events in 
Patients With Moderate to Severe 
Rheumatoid Arthritis)
A phase IV, 
randomized, open-
label, parallel-group, 
multicenter study
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Table 3. Ongoing phase III studies on drugs specifically targeting inflammation 
AIM DRUG TESTED PRIMARY ENDPOINT
Tests if reducing inflammation can 
reduce rates of recurrent 
cardiovascular events among stable 
post-myocardial infarction patients 
who remain at elevated vascular 
risk  (hsCRP ≥2mg/L) despite usual 
care, including statin therapy
Low-dose 
methotrexate
Composite of non-fatal 
myocardial infarction, non-
fatal stroke, or 
cardiovascular death
Tests if reducing inflammation 
among stable coronary artery 
disease patients (prior myocardial 
infarction or angiographically 
demonstrated multivessel coronary 
artery disease) with type 2 diabetes 
or metabolic syndrome can reduce 
rates of cardiovascular events 
Canakinumab, a 
human monoclonal 
antibody 
that neutralizes 
interleukin-1β
Composite of 
cardiovascular death, non-
fatal myocardial infarction 
and stroke
Evaluates the frequency of 
cardiovascular events on 
tocilizumab in comparison with 
etanercept in participants with 
rheumatoid arthritis.
Tocilizumab,  a 
humanized 
monoclonal antibody 
against the 
interleukin-6 receptor 
and etanercept a 
soluble TNF receptor
Composite of 
cardiovascular death, non-
fatal myocardial infarction 
and non-fatal stroke
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SECONDARY ENDPOINTS REFERENCES
Total mortality, hospitalization for 
unstable angina requiring 
revascularization, new onset 
diabetes
82
All-cause mortality, percutaneous 
or surgical coronary 
revascularization, hospitalization 
for congestive heart failure, incident 
venous thromboebolism,  incident 
atrial fibrillation, incident diabetes, 
Incident peripheral artery disease, 
clinically worsening aortic stenosis 
88, 89
A composite endpoint of major 
cardiovascular events plus non-
fatal coronary revascularization 
procedures and hospitalization for 
unstable angina; as well as 
investigating the frequency of 
adverse events and serious 
adverse events
90
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Bulletpoint Tables 
 
What is known about this topic? 
• Inflammation is an established mechanism for atherosclerosis 
inception, progression and complications, but its direct role in 
thrombosis, besides effects on the triggering substrate, is a much 
newer concept. 
• Trials with statins have shown a previously unexpected reduction in 
venous thromboembolism, fueling the concept of “inflammation-
triggered thrombosis” 
 
What does this paper add? 
• Here we review the multiple pathogenetic links between 
inflammation and thrombosis, and 
• Outline the ongoing trials with “pure” anti-inflammatory agents, now 
testing the hypothesis, all including venous thromboembolic episodes 
as endpoints. 
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